Christopher Bunka - Jan 7, 2025 Form 4 Insider Report for Lexaria Bioscience Corp. (LEXX)

Role
Director
Signature
/Chris Bunka/
Stock symbol
LEXX
Transactions as of
Jan 7, 2025
Transactions value $
$0
Form type
4
Date filed
1/10/2025, 11:52 AM
Previous filing
May 10, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LEXX Restricted Stock Award Award $0 +100K +36.56% $0.00 374K Jan 7, 2025 Direct F1, F2
holding LEXX common shares 274K Jan 7, 2025 Direct
holding LEXX common shares 254K Jan 7, 2025 Private Holding Company

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding LEXX Warrants 6.67K Jan 7, 2025 Common Shares 6.67K $10.50 Private Holding Company
holding LEXX Stock Options 32.7K Jan 7, 2025 Common Shares 26K $3.00 Direct
holding LEXX Stock Options 56K Jan 7, 2025 Common Shares 23.3K $3.00 Direct
holding LEXX Stock Options 71K Jan 7, 2025 Common Shares 15K $3.00 Direct
holding LEXX Stock Options 101K Jan 7, 2025 Common Shares 30K $2.91 Direct
holding LEXX Stock Options 131K Jan 7, 2025 Common Shares 30K $1.15 Direct
holding LEXX Stock Options 181K Jan 7, 2025 Common Shares 49.5K $2.36 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Beneficial ownership reflects the aggregate securities held directly.
F2 The closing price on the Issuer's shares on the date of grant was $2.24.